Acetazolamide Improves Right Ventricular Function and Metabolic Gene Dysregulation in Experimental Pulmonary Arterial Hypertension

Background: Right ventricular (RV) performance is a key determinant of mortality in pulmonary arterial hypertension (PAH). RV failure is characterized by metabolic dysregulation with unbalanced anaerobic glycolysis, oxidative phosphorylation, and fatty acid oxidation (FAO). We previously found that acetazolamide (ACTZ) treatment modulates the pulmonary inflammatory response and ameliorates experimental PAH. Objective: To evaluate the effect of ACTZ treatment on RV function and metabolic profile in experimental PAH. Design/Methods: In the Sugen 5416/hypoxia (SuHx) rat model of severe PAH, RV transcriptomic analysis was performed by RNA-seq, and top metabolic targets were validated by RT-PCR. We assessed the effect of therapeutic administration of ACTZ in the drinking water on hemodynamics by catheterization [right and left ventricular systolic pressure (RVSP and LVSP, respectively)] and echocardiography [pulmonary artery acceleration time (PAAT), RV wall thickness in diastole (RVWT), RV end-diastolic diameter (RVEDD), tricuspid annular plane systolic excursion (TAPSE)] and on RV hypertrophy (RVH) by Fulton's index (FI) and RV-to-body weight (BW) ratio (RV/BW). We also examined myocardial histopathology and expression of metabolic markers in RV tissues. Results: There was a distinct transcriptomic signature of RVH in the SuHx model of PAH, with significant downregulation of metabolic enzymes involved in fatty acid transport, beta oxidation, and glucose oxidation compared to controls. Treatment with ACTZ led to a pattern of gene expression suggestive of restored metabolic balance in the RV with significantly increased beta oxidation transcripts. In addition, the FAO transcription factor peroxisome proliferator-activated receptor gamma coactivator 1-alpha (Pgc-1α) was significantly downregulated in untreated SuHx rats compared to controls, and ACTZ treatment restored its expression levels. These metabolic changes were associated with amelioration of the hemodynamic and echocardiographic markers of RVH in the ACTZ-treated SuHx animals and attenuation of cardiomyocyte hypertrophy and RV fibrosis. Conclusion: Acetazolamide treatment prevents the development of PAH, RVH, and fibrosis in the SuHx rat model of severe PAH, improves RV function, and restores the RV metabolic profile.

[1]  J. Rabinowitz,et al.  Comprehensive quantification of fuel use by the failing and nonfailing human heart , 2020, Science.

[2]  F. Spyropoulos,et al.  Echocardiographic markers of pulmonary hemodynamics and right ventricular hypertrophy in rat models of pulmonary hypertension The first two authors contributed equally to this manuscript. , 2020, Pulmonary circulation.

[3]  H. Hudalla,et al.  Carbonic Anhydrase Inhibition Ameliorates Inflammation and Experimental Pulmonary Hypertension. , 2019, American journal of respiratory cell and molecular biology.

[4]  J. Nielsen-Kudsk,et al.  Right Ventricular Fibrosis: A Pathophysiological Factor in Pulmonary Hypertension? , 2019, Circulation.

[5]  T. Michel,et al.  Chemogenetic generation of hydrogen peroxide in the heart induces severe cardiac dysfunction , 2018, Nature Communications.

[6]  David E. Irwin,et al.  Vascular Adaptation of the Right Ventricle in Experimental Pulmonary Hypertension , 2018, American journal of respiratory cell and molecular biology.

[7]  Charles T. Hindmarch,et al.  Transcriptomic Signature of Right Ventricular Failure in Experimental Pulmonary Arterial Hypertension: Deep Sequencing Demonstrates Mitochondrial, Fibrotic, Inflammatory and Angiogenic Abnormalities , 2018, International journal of molecular sciences.

[8]  I. Douglas,et al.  Assessment of Right Ventricular Function in the Research Setting: Knowledge Gaps and Pathways Forward. An Official American Thoracic Society Research Statement , 2018, American journal of respiratory and critical care medicine.

[9]  G. Hansmann,et al.  PPARγ agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation , 2018, Science Translational Medicine.

[10]  M. Goumans,et al.  Contribution of Impaired Parasympathetic Activity to Right Ventricular Dysfunction and Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension , 2017, Circulation.

[11]  K. Wagner,et al.  Echocardiographic and Histological Examination of Cardiac Morphology in the Mouse. , 2017, Journal of visualized experiments : JoVE.

[12]  A. van Rossum,et al.  Renal Denervation Reduces Pulmonary Vascular Remodeling and Right Ventricular Diastolic Stiffness in Experimental Pulmonary Hypertension , 2017, JACC. Basic to translational science.

[13]  E. Michelakis,et al.  A Paradigm Shift Is Needed in the Field of Pulmonary Arterial Hypertension for Its Entrance Into the Precision Medicine Era. , 2016, Circulation research.

[14]  B. Alvarez,et al.  Carbonic anhydrase inhibitors reduce cardiac dysfunction after sustained coronary artery ligation in rats. , 2016, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[15]  B. Maron,et al.  Molecular Mechanisms of Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension , 2016, International journal of molecular sciences.

[16]  N. Serkova,et al.  Severe pulmonary hypertension is associated with altered right ventricle metabolic substrate uptake. , 2015, American journal of physiology. Lung cellular and molecular physiology.

[17]  E. Michelakis,et al.  Emerging therapies and future directions in pulmonary arterial hypertension. , 2015, The Canadian journal of cardiology.

[18]  L. Farkas,et al.  Iloprost reverses established fibrosis in experimental right ventricular failure , 2015, European Respiratory Journal.

[19]  E. Michelakis,et al.  The Metabolic Theory of Pulmonary Arterial Hypertension , 2014, Circulation research.

[20]  W. Fang,et al.  The Ratio of 18F-FDG Activity Uptake Between the Right and Left Ventricle in Patients With Pulmonary Hypertension Correlates With the Right Ventricular Function , 2014, Clinical nuclear medicine.

[21]  E. Michelakis,et al.  The metabolic basis of pulmonary arterial hypertension. , 2014, Cell metabolism.

[22]  L. Gleaves,et al.  Evidence for right ventricular lipotoxicity in heritable pulmonary arterial hypertension. , 2014, American journal of respiratory and critical care medicine.

[23]  E. Ruoslahti,et al.  A novel vascular homing peptide strategy to selectively enhance pulmonary drug efficacy in pulmonary arterial hypertension. , 2014, The American journal of pathology.

[24]  Robert L. Arechederra,et al.  Effect of sulfonamides as carbonic anhydrase VA and VB inhibitors on mitochondrial metabolic energy conversion. , 2013, Bioorganic & medicinal chemistry.

[25]  James D. Thomas,et al.  Fasting 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography to detect metabolic changes in pulmonary arterial hypertension hearts over 1 year. , 2013, Annals of the American Thoracic Society.

[26]  J. Bigbee,et al.  Metabolic Gene Remodeling and Mitochondrial Dysfunction in Failing Right Ventricular Hypertrophy Secondary to Pulmonary Arterial Hypertension , 2013, Circulation. Heart failure.

[27]  J. Loscalzo,et al.  Pulmonary hypertension: pathophysiology and signaling pathways. , 2013, Handbook of experimental pharmacology.

[28]  S. Kourembanas,et al.  Improved pulmonary vascular reactivity and decreased hypertrophic remodeling during nonhypercapnic acidosis in experimental pulmonary hypertension. , 2012, American journal of physiology. Lung cellular and molecular physiology.

[29]  J. Richalet,et al.  Acetazolamide and chronic hypoxia: effects on haemorheology and pulmonary haemodynamics , 2012, European Respiratory Journal.

[30]  W. Paulus,et al.  Bisoprolol Delays Progression Towards Right Heart Failure in Experimental Pulmonary Hypertension , 2012, Circulation. Heart failure.

[31]  N. Ozdemir,et al.  Increased Right Ventricular Glucose Metabolism in Patients With Pulmonary Arterial Hypertension , 2011, Clinical nuclear medicine.

[32]  J. Klinger,et al.  Bosentan attenuates right ventricular hypertrophy and fibrosis in normobaric hypoxia model of pulmonary hypertension. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[33]  P. Fawcett,et al.  Molecular signature of a right heart failure program in chronic severe pulmonary hypertension. , 2011, American journal of respiratory cell and molecular biology.

[34]  V. Beneš,et al.  The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. , 2009, Clinical chemistry.

[35]  L. Fredenburgh,et al.  Cyclooxygenase-2 inhibition and hypoxia-induced pulmonary hypertension: effects on pulmonary vascular remodeling and contractility. , 2009, Trends in cardiovascular medicine.

[36]  I. Haber,et al.  The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating right ventricle , 2009, Journal of Molecular Medicine.

[37]  Thomas D. Schmittgen,et al.  Analyzing real-time PCR data by the comparative CT method , 2008, Nature Protocols.

[38]  Claudiu T. Supuran,et al.  Carbonic anhydrases: novel therapeutic applications for inhibitors and activators , 2008, Nature Reviews Drug Discovery.

[39]  J. Bronzwaer,et al.  Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. , 2007, European heart journal.

[40]  E. Swenson,et al.  Inhibition of hypoxia-induced calcium responses in pulmonary arterial smooth muscle by acetazolamide is independent of carbonic anhydrase inhibition. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[41]  P. Light,et al.  Carbonic anhydrase inhibition prevents and reverts cardiomyocyte hypertrophy , 2007, The Journal of physiology.

[42]  Y. Kagaya,et al.  Increased [18F]fluorodeoxyglucose accumulation in right ventricular free wall in patients with pulmonary hypertension and the effect of epoprostenol. , 2005, Journal of the American College of Cardiology.

[43]  K. Sluka,et al.  Acetazolamide, a Carbonic Anhydrase Inhibitor, Reverses Inflammation-Induced Thermal Hyperalgesia in Rats , 2005, Journal of Pharmacology and Experimental Therapeutics.

[44]  C. Hsieh,et al.  Prevention of Hypoxia-Induced Pulmonary Hypertension by Enhancement of Endogenous Heme Oxygenase-1 in the Rat. • 238 , 1997, Pediatric Research.